^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
GeneseeqPrime™HRD

Company:
Geneseeq
Type:
CE Marked
Related tests:
Evidence

News

7ms
Geneseeq Gains CE Marks for NGS-based Test Kits for Solid Tumors and Hematological Cancer (Canada Newswire)
"Geneseeq Technology Inc. has announced that three of our next-generation sequencing (NGS)-based cancer genetic testing kits, GENESEEQPRIME NGS Tumor Gene Detection Kit (GeneseeqPrime ™), GENESEEQ Homologous Recombination Deficiency Detection Kit (GeneseeqPrime™ HRD), and GENESEEQ Blood Cancer Gene Detection Kit (Hemasalus™ DNA/Hemarna™ RNA), have obtained the European Union's CE Mark approval. These approvals signify that GeneseeqPrime™ and GeneseeqPrime™ HRD are suitable for solid tumor genomic profiling, while Hemasalus™ DNA/Hemarna™ RNA is cleared for hematological cancer genomic profiling."
European regulatory
|
GeneseeqPrime™ • GeneseeqPrime™HRD • Hemarna™ • Hemasalus™
over1year
Geneseeq, Brazilian Hospital partner on co-establishment of in-house NGS lab (Geneseeq Press Release)
"Geneseeq is teaming up with Hospital de Base in Sao José do Rio Preto, Brazil to build an NGS-based precision oncology diagnostic lab in-house to advance clinical research and offer comprehensive genetic testing to cancer patients in Brazil. Under the terms of the agreement, Geneseeq and Hospital de Base will co-build the NGS lab and establish a variety of Geneseeq’s NGS-based genomic profiling tests, consisting of comprehensive pan-cancer gene panels and cancer type-specific gene panels...The comprehensive panel GeneseeqPrime analyzes 437 cancer-related genes across all solid tumors while reporting microsatellite instability (MSI) and tumor mutation burden (TMB). GeneseeqPrime HRD, a test that integrates GeneseeqPrime with homologous recombination deficiency (HRD) score evaluation to inform the treatment selection of PARP inhibitors will also be available."
Licensing / partnership • Clinical
|
GeneseeqPrime™ • GeneseeqPrime™HRD